article thumbnail

Moderna says its coronavirus vaccine sparks immune response in older people

Bio Pharma Dive

An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.

article thumbnail

NIH study finds mixing COVID-19 boosters increases immune response

Bio Pharma Dive

Results suggested Pfizer's and Moderna's vaccines may serve as a more potent booster for those who initially received Johnson & Johnson's shot, although data are limited and preliminary.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Moderna vaccine safe and spurs immune response in kids, company says

Bio Pharma Dive

The trial results should allow the company to ask the FDA for approval of its vaccine in younger children, just as Pfizer nears a crucial decision for its shot in 5- to 11-year olds.

article thumbnail

Pfizer says coronavirus vaccine is safe and spurs immune response in children

Bio Pharma Dive

The results position Pfizer and BioNTech to seek clearance in children as young as five years old. But the companies haven't yet shared data on a rare heart inflammation associated with their shot that's a concern for regulators.

article thumbnail

Moderna says 'bivalent' booster sparks stronger immune response against omicron

Bio Pharma Dive

The biotech claims study results could position its reformulated vaccine as a booster in the fall, though it’s unclear how well the shot can prevent sickness caused by omicron or newer strains of the variant.

article thumbnail

Covid-19 induced immune response may damage brain, NINDS study finds

Pharmaceutical Technology

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

article thumbnail

Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot

Bio Pharma Dive

The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.